arrow
C

Christopher L. Moertel

university of minnesota
H指数:39
被引数:4,653

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CTNI-06. UPDATE FROM THE LONG-TERM FOLLOW-UP (LTFU) PHASE OF RENEU: A PIVOTAL PHASE 2B TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED SYMPTOMATIC PLEXIFORM NEUROFIBROMA (PN)

CTNI-06. RENEU长期随访(LTFU)阶段的更新:一项关于Mirdametinib在患有神经纤维瘤病1型(NF1)相关症状性丛状神经纤维瘤(PN)的儿童和成人中的关键性2B期试验

2025-11-110
OA
UNDERSTANDING COMMONLY REPORTED (≥15%) TREATMENT-RELATED ADVERSE EVENTS IN THE RENEU TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED PLEXIFORM NEUROFIBROMA (PN)

理解MIRDAMETINIB在RENEU试验中针对神经纤维瘤病1型(NF1)相关丛状神经纤维瘤(PN)的儿童和成人患者中常见报告的(≥15%)治疗相关不良事件

2025-11-010
OAAI
RENEU LONG-TERM FOLLOW-UP (LTFU) UPDATE: A PIVOTAL, PHASE 2B TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED SYMPTOMATIC PLEXIFORM NEUROFIBROMA (PN)

RENEU长期随访(LTFU)更新:一项关于Mirdametinib在患有1型神经纤维瘤病(NF1)相关症状性丛状神经纤维瘤(PN)的儿童和成人中的关键性、2B期试验

2025-10-010
OAAI
HEALTH-RELATED QUALITY-OF-LIFE (HRQOL) IN ADULTS AND CHILDREN WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN) TREATED WITH MIRDAMETINIB: PIVOTAL, PHASE 2B RENEU TRIAL
2024-11-110
PRE
OUTCOMES OF INFANTS AND YOUNG CHILDREN WITH NEWLY DIAGNOSED SHH MEDULLOBLASTOMA TREATED ON THE NEXT CONSORTIUM HEAD START 4 PROTOCOL
2024-06-180
OAAI
A PHASE 1/2 STUDY ASSESSING SAFETY AND PHARMACOKINETICS OF CEMIPLIMAB IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR CENTRAL-NERVOUS-SYSTEM TUMORS AND SAFETY AND EFFICACY OF CEMIPLIMAB IN COMBINATION WITH RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA, NEWLY DIAGNOSED HIGH-GRADE GLIOMA, OR RECURRENT HIGH-GRADE GLIOMA
2024-06-180
OAAI
DEMOGRAPHIC, CLINICAL AND IMAGING CHARACTERISTICS OF NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1: RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY
2024-06-180
OAAI
TUMOR VOLUME IN NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1 (NF1-OPG): PRELIMINARY RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY
2024-06-180
OAAI
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials
2023-10-251
PRE